Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 408734, 12 pages
http://dx.doi.org/10.1155/2013/408734
Research Article

Action Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia

1Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan
2Research Institute of Biotechnology, Hungkuang University, 34 Chung-Chie Road, Shalu District, Taichung City 43302, Taiwan
3Department of Urology, Shuang Ho Hospital, Taipei Medical University, 291 Zhongzheng Road, Zhonghe, Taipei 23561, Taiwan
4Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11031, Taiwan
5Division of Urology, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen Chang Road, Taipei 111, Taiwan

Received 11 December 2012; Revised 26 January 2013; Accepted 26 January 2013

Academic Editor: Gerhard Litscher

Copyright © 2013 Chiung-Chi Peng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. T. McVary, “BPH: epidemiology and comorbidities,” American Journal of Managed Care, vol. 12, no. 5, supplement, pp. S122–S128, 2006. View at Google Scholar · View at Scopus
  2. T. M. Nicholson and W. A. Ricke, “Androgens and estrogens in benign prostatic hyperplasia: past, present and future,” Differentiation, vol. 82, no. 4-5, pp. 184–199, 2011. View at Google Scholar
  3. J. McNeal, “Pathology of benign prostatic hyperplasia. Insight into etiology,” Urologic Clinics of North America, vol. 17, no. 3, pp. 477–486, 1990. View at Google Scholar · View at Scopus
  4. G. Untergasser, S. Madersbacher, and P. Berger, “Benign prostatic hyperplasia: age-related tissue-remodeling,” Experimental Gerontology, vol. 40, no. 3, pp. 121–128, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Lucia and J. R. Lambert, “Growth factors in benign prostatic hyperplasia: basic science implications,” Current Urology Reports, vol. 9, no. 4, pp. 272–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Sciarra, G. Mariotti, S. Salciccia et al., “Prostate growth and inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 108, no. 3–5, pp. 254–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. K. M. Ho and F. K. Habib, “Estrogen and androgen signaling in the pathogenesis of BPH,” Nature Reviews Urology, vol. 8, no. 1, pp. 29–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Tsurusaki, D. Aoki, H. Kanetake et al., “Zone-dependent expression of estrogen receptors α and β in human benign prostatic hyperplasia,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 3, pp. 1333–1340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Alonso-Magdalena, C. Brössner, A. Reiner et al., “A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2859–2863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Y. Lin and H. P. Chang, “Induction of superoxide dismutase and catalase activity in different rat tissues and protection from UVB irradiation after topical application of Ginkgo biloba extracts,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 19, no. 6, pp. 367–371, 1997. View at Google Scholar · View at Scopus
  11. A. P. Berger, K. Kofler, J. Bektic et al., “Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia,” Prostate, vol. 57, no. 1, pp. 57–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Kramer, D. Mitteregger, and M. Marberger, “Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?” European Urology, vol. 51, no. 5, pp. 1202–1216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Novara, A. Galfano, V. Ficarra, and W. Artibani, “Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review,” European Urology, vol. 50, no. 4, pp. 675–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. N. B. Delongchamps, G. de la Roza, V. Chandan et al., “Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer?” Journal of Urology, vol. 179, no. 5, pp. 1736–1740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Nickel, C. G. Roehrborn, M. P. O'Leary, D. G. Bostwick, M. C. Somerville, and R. S. Rittmaster, “Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial,” Journal of Urology, vol. 178, no. 3, pp. 896–901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Alcaraz, P. Hammerer, A. Tubaro, F. H. Schröder, and R. Castro, “Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review,” European Urology, vol. 55, no. 4, pp. 864–873, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. C. G. Roehrborn, J. Barkin, P. Siami et al., “Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-Year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial,” Journal of the British Association of Urological Surgeons, vol. 107, no. 6, pp. 946–954, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. S. Gerber, “Phytotherapy for benign prostatic hyperplasia,” Current Urology Reports, vol. 3, no. 4, pp. 285–291, 2002. View at Google Scholar · View at Scopus
  19. J. A. Thomas, “Diet, micronutrients, and the prostate gland,” Nutrition Reviews, vol. 57, no. 4, pp. 95–103, 1999. View at Google Scholar · View at Scopus
  20. B. Singh, P. Kaur, Gopichand, R. D. Singh, and P. S. Ahuja, “Biology and chemistry of Ginkgo biloba,” Fitoterapia, vol. 79, no. 6, pp. 401–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Gohil, R. K. Moy, S. Farzin, J. J. Maguire, and L. Packer, “MRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: induction of antioxidant response and the golgi system,” Free Radical Research, vol. 33, no. 6, pp. 831–849, 2000. View at Google Scholar · View at Scopus
  22. R. Bridi, F. P. Crossetti, V. M. Steffen, and A. T. Henriques, “The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats,” Phytotherapy Research, vol. 15, no. 5, pp. 449–451, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. X. Chen, H. Zeng, X. Chen, C. Y. Su, and C. C. Lai, “Induction of oxygenase-1 by Ginkgo biloba extract but not its terpenoids partially mediated its protective effect against lysophosphatidylcholine-induced damage,” Pharmacological Research, vol. 43, no. 1, pp. 63–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ahmad, S. Saleem, A. S. Ahmad et al., “Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences,” Journal of Neurochemistry, vol. 93, no. 1, pp. 94–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. F. V. DeFeudis, “A brief history of EGb 761 and its therapeutic uses,” Pharmacopsychiatry, vol. 36, supplement 1, pp. S2–S7, 2003. View at Google Scholar · View at Scopus
  26. G. R. Shah, M. V. Chaudhari, S. B. Patankar et al., “Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study,” BMC Complementary and Alternative Medicine, vol. 12, pp. 155–163, 2012. View at Google Scholar
  27. J. Sea, K. S. Poon, and K. T. McVary, “Review of exercise and the risk of benign prostatic hyperplasia,” The Physician and Sportsmedicine, vol. 37, no. 4, pp. 75–83, 2009. View at Google Scholar · View at Scopus
  28. P. T. Williams, “Effects of running distance and performance on incident benign prostatic hyperplasia,” Medicine and Science in Sports and Exercise, vol. 40, no. 10, pp. 1733–1739, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Suzuki, Y. Takezawa, T. Suzuki, S. Honma, and H. Yamanaka, “Synergistic effects of estrogen with androgen on the prostate—effects of estrogen on the prostate of androgen-administered rats and 5-alpha-reductase activity,” Prostate, vol. 25, no. 4, pp. 169–176, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. K. C. Chen, C. L. Hsieh, C. C. Peng, and R. Y. Peng, “Exercise rescued chronic kidney disease by attenuating cardiac hypertrophy through the cardiotrophin-1 → LIFR/gp 130 →JAK/STAT3 pathway,” European Journal of Preventive Cardiology, 2012. View at Publisher · View at Google Scholar
  31. J. S. Chen, Y. H. Chen, P. H. Huang et al., “Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathways,” Cardiovascular Diabetology, vol. 11, p. 49, 2012. View at Google Scholar
  32. J. Ma, M. Gharaee-Kermani, L. Kunju et al., “Prostatic fibrosis is associated with lower urinary tract symptoms,” Journal of Urology, vol. 188, no. 4, pp. 1375–1381, 2012. View at Google Scholar
  33. C. Ulman, G. Buyukyazi, F. Taneli, and B. S. Uyanik, “Recreational and master athletic activity does not affect free and total prostate-specific antigen levels but lowers the free-to-total prostate-specific antigen ratio,” Journal of International Medical Research, vol. 32, no. 6, pp. 583–589, 2004. View at Google Scholar · View at Scopus
  34. S. M. Oh and K. H. Chung, “Antiestrogenic activities of Ginkgo biloba extracts,” Journal of Steroid Biochemistry and Molecular Biology, vol. 100, no. 4-5, pp. 167–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Giri and M. Ittmann, “Interleukin-1α is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia,” American Journal of Pathology, vol. 157, no. 1, pp. 249–255, 2000. View at Google Scholar · View at Scopus
  36. F. Deng, F. Gu, and T. Xia, “Proliferation and apoptosis status in benign prostatic hyperplasia,” Zhonghua Wai Ke Za Zhi, vol. 34, no. 10, pp. 620–622, 1996. View at Google Scholar · View at Scopus